Shots:

• Merck will spin-off its women’s health- trusted legacy brands and biosimilars businesses into a new company with an objective to retain its focus in its core therapy areas including oncology- vaccines- hospital & animal health
• NewCo will focus on women health’s product- Nexplanon (etonogestrel implant) franchise and fueled by its leading contraceptive and fertility businesses and is expected to work on biosimilar therapies including Renflexis (infliximab-abda) and Brenzys (etanercept) in immunology and Ontruzant (trastuzumab-dttb) in oncology
• NewCo will also focus on trusted brands consisting of Zetia (ezetimibe) & Vytorin (ezetimibe/simvastatin). The transaction enables Merck to achieve in excess $1.5B in operating efficiencies by 2024 with its anticipated completion in H1’21

Click here ­to­ read full press release/ article 

Ref: PRNewswire | Image: Merck